Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TARS | US
1.14
3.48%
Healthcare
Biotechnology
30/06/2024
04/10/2024
33.89
32.97
35.62
32.57
Tarsus Pharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03 a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition the company develops lotilaner to address diseases across therapeutic categories in human medicine including eye care dermatology and other diseases. Tarsus Pharmaceuticals Inc. was incorporated in 2016 and is headquartered in Irvine California.
View LessStrength based on increasing price with high volume
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
36.2%1 month
71.7%3 months
68.8%6 months
63.2%-
-
4.90
0.29
0.19
-3.23
11.82
-
-155.27M
1.31B
1.31B
-
-81.60
-
1.00K
-75.04
13.84
25.87
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.26
Range1M
9.80
Range3M
15.54
Rel. volume
1.09
Price X volume
24.56M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Dynavax Technologies Corporation | DVAX | Biotechnology | 11.02 | 1.44B | -2.91% | 84.62 | 39.71% |
NRIX | NRIX | Biotechnology | 22.2 | 1.43B | 1.05% | n/a | 7.77% |
Longboard Pharmaceuticals Inc. Common Stock | LBPH | Biotechnology | 36.22 | 1.41B | -0.55% | n/a | 1.31% |
Xencor Inc | XNCR | Biotechnology | 19.85 | 1.39B | 2.00% | n/a | 15.54% |
Day One Biopharmaceuticals Inc. Common Stock | DAWN | Biotechnology | 14.1 | 1.39B | 3.52% | n/a | 0.06% |
Kura Oncology Inc | KURA | Biotechnology | 18.04 | 1.38B | -2.49% | n/a | 3.59% |
SPRY | SPRY | Biotechnology | 14.19 | 1.38B | -1.80% | n/a | 0.07% |
ELVN | ELVN | Biotechnology | 27.53 | 1.30B | 8.81% | n/a | 0.06% |
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 13.09 | 1.26B | 0.23% | n/a | 53.59% |
Mesoblast Limited | MESO | Biotechnology | 10.81 | 1.26B | 23.40% | n/a | 24.76% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.23 | 0.76 | Cheaper |
Ent. to Revenue | 11.82 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 4.90 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 68.81 | 74.67 | Par |
Debt to Equity | 0.29 | -1.82 | Expensive |
Debt to Assets | 0.19 | 0.26 | Cheaper |
Market Cap | 1.31B | 3.73B | Emerging |